Rapidly progressive dementia by late neurosyphilis (general paresis). Case report
Main Article Content
Keywords
Abstract
Background: The term rapidly progressive dementia (RPD) describes a disorder with rapid progression which leads to a major cognitive decline in less than 1 or 2 years. Neurosyphilis is an infectious cause of RPD and it is classified clinically into early and late forms. The latter affect the brain and spinal cord parenchyma. The objective of this report is to present a case of RPD caused by neurosyphilis.
Clinical case: 55-year-old man, with no past medical history, who in July 2022 had a clinical presentation of aggressiveness, irritability, lability, difficulty in performing simple activities, amnesia, hallucinations, delusions, abulia, low responsiveness, all of which affected his independence and quality of life. Initially, it was treated as schizophrenia with no signs of improvement and clinical deterioration. When atypical data and rapid progression were evident at patient’s consultation in January 2023, there was a suspicion of the presence of RPD, highlighting positive VDRL and IgM-IgG anti-Treponema pallidum antibodies in cerebrospinal fluid (CSF). Computed tomography (CT) and magnetic resonance imaging (MRI) showed global cortical atrophy, predominantly frontal. Treatment with ceftriaxone was started for 14 days, with clinical improvement observed in the MOCA test from 13/30 to 23/30.
Conclusions: The etiological identification of RPD is a clinical challenge due to the wide variety of causes, which is why it is important a specific diagnostic approach and a timely treatment in order to avoid the progression of potentially reversible causes.
References
Hermann P, Zerr I. Rapidly progressive dementias - aetiologies, diagnosis and management. Nat Rev Neurol. 2022;18(6):363–76. doi: 10.1038/s41582-022-00659-0.
Day GS. Rapidly progressive dementia. Continuum (Minneap Minn). 2022;28(3):901-36. doi: 10.1212/CON.0000000000001089.
Chow F. Neurosyphilis. Continuum (Minneap Minn). 2021;27(4):1018-39. doi: 10.1212/CON.0000000000000982.
Ghanem KG, Ram S, Rice PA. The modern epidemic of syphilis. N Engl J Med. 2020;382(9):845-54. doi: 10.1056/NEJMra1901593.
Hamill MM, Ghanem KG, Tuddenham S. State-of-the-Art Review: Neurosyphilis. Clin Infect Dis. 2024;78(5):e57-e68. doi: 10.1093/cid/ciad437.
González-Martínez P, Oltra-Cucarella J, Sitges-Maciá E, et al. Revisión y actualización de los criterios de deterioro cognitivo objetivo y su implicación en el deterioro cognitivo leve y la demencia. Rev Neurol. 2021;72(08):288. doi: 10.33588/rn.7208.2020626.
Liu X, Sun Y, Zhang X, et al. Prevalence and outcomes of rapidly progressive dementia: a retrospective cohort study in a neurologic unit in China. BMC Geriatr. 2023;23(1). doi: 10.1186/s12877-023-03841-1.
Anuja P, Venugopalan V, Darakhshan N, et al. Rapidly progressive dementia: An eight year (2008–2016) retrospective study. PLoS One. 2018;13(1):e0189832. doi: 10.1371/journal.pone.0189832.
Jackson DA, McDonald R, Quilter LAS, et al. Reported neurologic, ocular, and otic manifestations among syphilis cases—16 states, 2019. Sex Transm Dis. 2022;49(10):726-32. doi: 10.1097/olq.0000000000001673.
Day GS. Reversible dementias. Continuum (Minneap Minn). 2019;25(1):234-53. doi: 10.1212/con.0000000000000688.
Ropper AH. Neurosyphilis. N Engl J Med. 2019;381(14):1358-63. doi: 10.1056/nejmra1906228.
Vadboncoeur J, Labbé A-C, Fortin C, et al. Ocular syphilis: case series (2000–2015) from 2 tertiary care centres in Montreal, Canada. Can J Ophthalmol. 2020;55(1):30-7. doi: 10.1016/j.jcjo.2019.05.009.
Workowski KA, Bachmann LH. Centers for Disease Control and Prevention’s sexually transmitted diseases infection guidelines. Clin Infect Dis. 2022;74(Supplement_2):S89-94. doi: 10.1093/cid/ciab1055.
Arando-Lasagabaster M, Otero-Guerra L. Sífilis. Enferm Infecc Microbiol Clin. 2019;37(6):398-404. doi: 10.1016/j.eimc.2018.12.009.
Janier M, Unemo M, Dupin N, et al. 2020 European guideline on the management of syphilis. J Eur Acad Dermatol Venereol. 2021;35(3):574-88. doi: 10.1111/jdv.16946.
Raji CA, Benzinger TLS. The value of neuroimaging in dementia diagnosis. Continuum (Minneap Minn). 2022;28(3):800-21. doi: 10.1212/con.0000000000001133.
Buitrago-Garcia D, Martí-Carvajal AJ, Jimenez A, et al. Antibiotic therapy for adults with neurosyphilis. Cochrane Libr. 2019;2019(5). doi: 10.1002/14651858.cd011399.pub2.
Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):39-46. doi: 10.15585/mmwr.rr7004a.
Dunaway SB, Maxwell CL, Tantalo LC, et al. Neurosyphilis treatment outcomes after intravenous penicillin G versus intramuscular procaine penicillin plus oral probenecid. Clin Infect Dis . 2020;71(2):267-73. doi: 10.1093/cid/ciz795.
Bettuzzi T, Jourdes A, Robineau O, et al. Ceftriaxone compared with benzylpenicillin in the treatment of neurosyphilis in France: a retrospective multicentre study. Lancet Infect Dis. 2021;21(10):1441-7. doi: 10.1016/s1473-3099(20)30857-4f.